# A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus

> **NCT07662044** · PHASE3 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 800 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Elecoglipron
- **DRUG:** Dapagliflozin
- **DRUG:** Elecoglipron-matched placebo
- **DRUG:** Dapagliflozin-matched placebo

## Key facts

- **NCT ID:** NCT07662044
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-06
- **Primary completion:** 2028-07-14
- **Final completion:** 2028-07-14
- **Target enrollment:** 800 (ESTIMATED)
- **Last updated:** 2026-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07662044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07662044, "A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07662044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*